Whitehawk Therapeutics (WHWK) CMO receives 19,132-share stock grant at $3.92

Rhea-AI Filing Summary

Dugan Margaret reported acquisition or exercise transactions in this Form 4 filing.

Whitehawk Therapeutics, Inc. reported that its Chief Medical Officer, Margaret Dugan, received a grant of 19,132 shares of common stock on May 14, 2026. The shares were valued at $3.92 per share for reporting purposes, bringing her direct holdings to 19,132 shares. This is a compensation-related award, not an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Dugan Margaret

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	19,132	$3.92	$75K

Holdings After Transaction: Common Stock — 19,132 shares (Direct, null)

Footnotes (1)

Key Figures

Share grant size: 19,132 shares Reported price per share: $3.92 per share Total direct holdings after grant: 19,132 shares

3 metrics

Share grant size 19,132 shares Common Stock grant on May 14, 2026

Reported price per share $3.92 per share Value used for the 19,132-share grant

Total direct holdings after grant 19,132 shares Shares of Common Stock held directly following transaction

Key Terms

Grant, award, or other acquisition, Form 4, Chief Medical Officer

3 terms

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Chief Medical Officer financial

"officer_title: "Chief Medical Officer""

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dugan Margaret

(Last) (First) (Middle)

C/O WHITEHAWK THERAPEUTICS, INC.

2 HEADQUARTERS PLAZA, EAST BUILDING, 11T

(Street)

MORRISTOWN NEW JERSEY 07960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Whitehawk Therapeutics, Inc. [ WHWK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		A		19,132	A	$3.92	19,132	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Stephen Rodin, as Attorney-in-Fact	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Whitehawk Therapeutics (WHWK) disclose for Margaret Dugan?

Whitehawk Therapeutics disclosed that Chief Medical Officer Margaret Dugan received a grant of 19,132 common shares. The award was reported at $3.92 per share and is characterized as a grant, award, or other acquisition, reflecting equity-based compensation rather than an open-market stock purchase.

Was the WHWK insider transaction by Margaret Dugan a stock purchase or a grant?

The WHWK insider transaction was a grant, not an open-market purchase. Form 4 describes it as a “Grant, award, or other acquisition,” indicating compensation-related equity. The 19,132 shares of common stock were reported at $3.92 per share for disclosure purposes.

How many Whitehawk Therapeutics shares does Margaret Dugan hold after this Form 4?

After this Form 4 transaction, Margaret Dugan holds 19,132 shares of Whitehawk Therapeutics common stock directly. This entire amount comes from the reported grant on May 14, 2026, and there are no additional derivative positions disclosed in this filing’s derivative summary.

What role does Margaret Dugan hold at Whitehawk Therapeutics (WHWK)?

Margaret Dugan serves as Chief Medical Officer at Whitehawk Therapeutics. The Form 4 identifies her as an officer with this title, and the 19,132-share grant of common stock reflects equity compensation associated with her executive role at the company.

What was the reported price per share for Margaret Dugan’s WHWK stock grant?

The reported price per share for Margaret Dugan’s Whitehawk Therapeutics stock grant was $3.92. Form 4 uses this figure as the transaction price per share when disclosing the 19,132-share grant of common stock received on May 14, 2026, as equity compensation.